We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Smartphone App Helps Screen Populations for Atrial Fibrillation

By HospiMedica International staff writers
Posted on 03 Nov 2016
Researchers at Princess Margaret Hospital (PMH; Hong Kong) conducted a study involving 13,122 Hong Kong citizens who consented and voluntarily participated in a territory-wide AF screening program between May 1, 2014, and April 30, 2015. More...
The purpose of the study was to assess the feasibility of community screening using a smartphone-based wireless single-lead ECG (SL-ECG) and to generate epidemiological data on the prevalence and risk factors of AF in Hong Kong.

The 30-second test showed that 8.5% of those tested had AF, 101 cases (or 0.8%) of which had not been previously diagnosed; results were uninterpretable in only 0.4% of those tested. The AF fraction points to a disease prevalence comparable to that of populations in other developed countries. In two thirds of the new cases, the condition was symptomless, but their combined risk scores suggest that they would have benefited from treatment. The study was published on October 12, 2016, in Heart.

“Community screening for AF with SL-ECG was feasible, and it identified a significant proportion of citizens with newly diagnosed AF,” concluded study authors Ngai-yin Chan, MD, and Chi-chung Choy, MD, of PMH. “Increasing age (60+), male sex, weight, and a history of heart disease/surgery and peripheral vascular disease were all predictive of the condition.”

“In order to relieve both patients and society from the consequences of untreated AF, we believe and hope that AF screening in risk groups will be a part of the standard healthcare in many countries in the near future,” commented Emma Svennberg, MD, of the Karolinska Institute (Stockholm, Sweden), and Johan Engdahl, MD, of the Sahlgrenska Academy (Göteborg, Sweden), in an accompanying editorial. “Besides, isn't it encouraging that we can use our smartphones to search for other things than Pokémons?”

AF is the most common heart rhythm disorder, affecting more than 30 million people worldwide, with five million new cases reported annually. Accurate diagnosis of AF is critical because antithrombotic treatment significantly reduces the risk of recurrent embolism and death. Treatment options include medications, which do not address the underlying problem, and minimally invasive, catheter-based ablation procedures, which are designed to disrupt the transmission of abnormal impulses in the heart.

Related Links:
Princess Margaret Hospital


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.